This article is more than 5 years old. Information may no longer be current.
7 recent studies highlighting PCI trends
Click Here to Manage Email Alerts
PCI is a nonsurgical procedure performed to treat atherosclerosis.
This month, there has been an increased focus on studies that look at the risks for patients undergoing or who have received PCI.
Cardiology Today’s Intervention has compiled a list of seven articles published this month discussing trends in PCI, as well as the risks involved for those undergoing the procedure.
Complex target lesion anatomy linked to increased ischemic events
Complex target lesion anatomy stenting is associated with increased ischemic event rates in patients undergoing PCI, especially within the first year, according to new data.
“Among patients enrolled and randomized in the DAPT study, we found that those undergoing PCI with more complex coronary artery target lesions had a higher rate of subsequent ischemic events, particularly within the first year after PCI compared with patients without complex lesions,” Robert W. Yeh, MD, MSc, from the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center, and colleagues wrote. “After the first year, this association was attenuated.”
Smoking rates remain high after PCI, CABG
Among smokers who underwent coronary revascularization, rates of smoking remained substantial despite smoking cessation efforts, researchers reported.
Kudret Keskin, MD, of the cardiology department at the Medicana Hospitals Bahçelievler, Eski Londra AsfaltI Haznedar in Istanbul, and colleagues studied 350 smokers who had undergone coronary revascularization by PCI or CABG, to assess rates of smoking after intervention. They presented their findings at the Emirates Cardiac Society Congress in collaboration with the American College of Cardiology Middle East Conference in Dubai, United Arab Emirates.
Risk for recurrent ischemic events increased in women, minorities after PCI
Women and minorities who underwent contemporary everolimus-eluting stent implantation had an increased risk for recurrent ischemic events compared with white men, and all three groups had similar risk for MACE at 1 year, according to a study published in JAMA Cardiology.
Overlapping scaffolds associated with increased periprocedural MI
Overlapping of bioresorbable vascular scaffolds was linked to increased rates of periprocedural MI but no immediate or long-term effects on cardiac death, target lesion revascularization or stent thrombosis, according to the results of the ABSORB EXTEND trial.
Bioresorbable scaffolds increase risk for thrombotic events vs. drug-eluting stents
At mid- and long-term follow-up, the risks for scaffold thrombosis and other thrombotic events were elevated in adults who received bioresorbable vascular scaffolds compared with everolimus-eluting metallic stents, according to findings published in Annals of Internal Medicine.
Major bleeding, regardless of definition, confers mortality risk after PCI
Severe or major bleeding as defined by each of four bleeding scales at 48 hours after PCI was linked to elevated risk for 30-day and 1-year mortality, according to an analysis of the CHAMPION trials.
In the CHAMPION trials — CHAMPION PCI, CHAMPION PHOENIX and CHAMPION PLATFORM — patients undergoing PCI were assigned cangrelor (Kengreal, Chiesi) or clopidogrel for P2Y12 inhibition.
DCB, newer DES similar in outcomes for coronary in-stent restenosis
Drug-coated balloons and second-generation drug-eluting stents were equally effective in treating coronary in-stent restenosis, according to a new systematic review and meta-analysis.
Although there was no difference between the technologies in all-cause mortality in randomized controlled trials, second-generation DES were associated with lower all-cause mortality in observational studies compared with DCB, according to the researchers.